NASDAQ:TXG 10x Genomics - TXG Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $48.65 +0.62 (+1.29%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$46.94▼$48.7850-Day Range$31.68▼$48.6552-Week Range$23.81▼$100.00Volume696,676 shsAverage Volume1.14 million shsMarket Capitalization$5.57 billionP/E RatioN/ADividend YieldN/APrice Target$51.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability 10x Genomics MarketRank™ ForecastAnalyst RatingHold2.44 Rating ScoreUpside/Downside4.8% Upside$51.00 Price TargetShort InterestHealthy7.24% of Float Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment1.19Based on 6 Articles This WeekInsider TradingSelling Shares$227,008 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.60) to ($1.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector776th out of 1,055 stocksAnalytical Instruments Industry23rd out of 28 stocks 1.2 Analyst's Opinion Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 6 buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.00, 10x Genomics has a forecasted upside of 4.8% from its current price of $48.65.Amount of Analyst Coverage10x Genomics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.24% of the float of 10x Genomics has been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in 10x Genomics has recently decreased by 16.89%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) Score10x Genomics has received a 76.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for 10x Genomics is -0.90. Previous Next 2.9 News and Social Media Coverage News Sentiment10x Genomics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for 10x Genomics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $227,008.00 in company stock.Percentage Held by Insiders11.08% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.34% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.60) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -32.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -32.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 6.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 10x Genomics (NASDAQ:TXG) Stock10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Stock News HeadlinesJanuary 26, 2023 | reuters.comTXG.O - | Stock Price & Latest News | ReutersJanuary 19, 2023 | finance.yahoo.com10x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023January 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 10, 2023 | finance.yahoo.com10x Genomics toolkit ‘at the fulcrum of innovation,’ CEO saysDecember 28, 2022 | finance.yahoo.com10x Genomics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 27, 2022 | seekingalpha.com10x Genomics: Long-Term Growth Potential Marred By Near-Term Funding RisksDecember 22, 2022 | finance.yahoo.com10x Genomics (NASDAQ:TXG) adds US$133m to market cap in the past 7 days, though investors from a year ago are still down 75%December 19, 2022 | msn.com10x Genomics Earnings Perspective: Return On Capital EmployedJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 8, 2022 | finance.yahoo.com10x Genomics Commercially Launches Xenium Platform for In Situ AnalysisDecember 6, 2022 | bizjournals.comEast Bay startup Infinimmune's secret for building better antibody drugs: YouDecember 1, 2022 | finance.yahoo.comAt US$38.66, Is It Time To Put 10x Genomics, Inc. (NASDAQ:TXG) On Your Watch List?November 16, 2022 | msn.com10x Genomics's Return On Capital Employed InsightsNovember 9, 2022 | finance.yahoo.com10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor DiscoveryNovember 9, 2022 | finance.yahoo.com10x Genomics Third Quarter 2022 Earnings: Beats ExpectationsNovember 7, 2022 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), Avanos Medical (AVNS) and 10x Genomics (TXG)November 4, 2022 | finance.yahoo.comHere’s Why 10x Genomics (TXG) Underperformed in the Third QuarterNovember 4, 2022 | finance.yahoo.com10x Genomics, Inc.'s (NASDAQ:TXG) Intrinsic Value Is Potentially 99% Above Its Share PriceNovember 3, 2022 | seekingalpha.com10x Genomics, Inc. (TXG) Q3 2022 Earnings Call TranscriptNovember 2, 2022 | markets.businessinsider.com10x Genomics Reports Third Quarter 2022 Financial ResultsNovember 1, 2022 | finance.yahoo.com10x Genomics to Host Investor Day on December 8, 2022October 24, 2022 | finance.yahoo.comPacBio's (PACB) Latest Offering to Enhance Disease DiscoveriesOctober 24, 2022 | finance.yahoo.comPacific Biosciences' Tools Expansion Doesn't Guarantee SuccessOctober 12, 2022 | finance.yahoo.com10x Genomics to Report Third Quarter Financial Results on November 2, 2022October 3, 2022 | finance.yahoo.comA Strong Dollar Could Whack These Biotech StocksSeptember 23, 2022 | finance.yahoo.com10x Genomics (NASDAQ:TXG) Is In A Good Position To Deliver On Growth PlansSeptember 2, 2022 | finance.yahoo.com10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Company Calendar Last Earnings11/02/2022Today1/28/2023Next Earnings (Confirmed)2/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXG CUSIPN/A CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,239Year FoundedN/APrice Target and Rating Average Stock Price Forecast$51.00 High Stock Price Forecast$65.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+4.8%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,220,000.00 Net Margins-33.20% Pretax Margin-32.07% Return on Equity-21.01% Return on Assets-16.64% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.34 Sales & Book Value Annual Sales$490.49 million Price / Sales11.35 Cash FlowN/A Price / Cash FlowN/A Book Value$7.27 per share Price / Book6.69Miscellaneous Outstanding Shares114,460,000Free Float101,781,000Market Cap$5.57 billion OptionableOptionable Beta1.68 Key ExecutivesDr. Serge Saxonov Ph.D. (Age 46)Co-Founder, CEO & Director Comp: $736.52kDr. Benjamin J. Hindson Ph.D. (Age 48)Co-Founder, Pres, Chief Scientific Officer & Director Comp: $496kMr. Justin J. McAnear (Age 47)Chief Financial Officer Comp: $470.4kMr. Eric S. Whitaker Esq. (Age 56)Chief Legal Officer Comp: $505kMr. Michael Schnall-LevinFounding Scientist & CTOMs. Cassie CorneauMang. of Investor Relations and Strategic Fin.Mr. Jonathan SchimmelVP of Global Support & Sales OperationsMs. Rebecca PortChief People OfficerMs. Ruth De Backer (Age 46)Chief Bus. Officer Mr. Jim Wilbur Ph.D.Chief Commercial OfficerMore ExecutivesKey CompetitorsPacific Biosciences of CaliforniaNASDAQ:PACBOlink Holding AB (publ)NASDAQ:OLKCytek BiosciencesNASDAQ:CTKBBio-Rad LaboratoriesNYSE:BIO.BBio-Rad LaboratoriesNYSE:BIOView All CompetitorsInsiders & InstitutionsNordwand Advisors LLCBought 135,958 shares on 1/27/2023Ownership: 0.119%Dupont Capital Management CorpBought 3,368 shares on 1/26/2023Ownership: 0.003%K.J. Harrison & Partners IncBought 4,060 shares on 1/25/2023Ownership: 0.004%Baillie Gifford & Co.Bought 158,847 shares on 1/24/2023Ownership: 7.515%Xponance Inc.Bought 1,138 shares on 1/24/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions TXG Stock - Frequently Asked Questions Should I buy or sell 10x Genomics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXG, but not buy additional shares or sell existing shares. View TXG analyst ratings or view top-rated stocks. What is 10x Genomics' stock price forecast for 2023? 9 equities research analysts have issued twelve-month target prices for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $65.00. On average, they expect the company's stock price to reach $51.00 in the next twelve months. This suggests a possible upside of 4.8% from the stock's current price. View analysts price targets for TXG or view top-rated stocks among Wall Street analysts. How have TXG shares performed in 2023? 10x Genomics' stock was trading at $36.44 at the beginning of 2023. Since then, TXG stock has increased by 33.5% and is now trading at $48.65. View the best growth stocks for 2023 here. Are investors shorting 10x Genomics? 10x Genomics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,200,000 shares, a decline of 16.9% from the December 31st total of 7,460,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is currently 4.6 days. Currently, 7.2% of the shares of the company are sold short. View 10x Genomics' Short Interest. When is 10x Genomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023. View our TXG earnings forecast. How can I listen to 10x Genomics' earnings call? 10x Genomics will be holding an earnings conference call on Wednesday, February 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) issued its quarterly earnings data on Wednesday, November, 2nd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The company had revenue of $131.10 million for the quarter, compared to analyst estimates of $129.13 million. 10x Genomics had a negative trailing twelve-month return on equity of 21.01% and a negative net margin of 33.20%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.15) earnings per share. What guidance has 10x Genomics issued on next quarter's earnings? 10x Genomics updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $500.00 million-$520.00 million, compared to the consensus revenue estimate of $509.87 million. What is Serge Saxonov's approval rating as 10x Genomics' CEO? 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did 10x Genomics IPO? (TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager. What is 10x Genomics' stock symbol? 10x Genomics trades on the NASDAQ under the ticker symbol "TXG." Who are 10x Genomics' major shareholders? 10x Genomics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (7.52%), ARK Investment Management LLC (3.77%), Financial Consulate Inc. (0.14%), Nordwand Advisors LLC (0.12%), Allworth Financial LP (0.02%) and Capricorn Fund Managers Ltd (0.01%). Insiders that own company stock include Associates Vi LP Venrock, Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, Bryan E Roberts, Foresite Capital Management I,, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Serge Saxonov and Sridhar Kosaraju. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 10x Genomics' stock price today? One share of TXG stock can currently be purchased for approximately $48.65. How much money does 10x Genomics make? 10x Genomics (NASDAQ:TXG) has a market capitalization of $5.57 billion and generates $490.49 million in revenue each year. The company earns $-58,220,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. How many employees does 10x Genomics have? The company employs 1,239 workers across the globe. How can I contact 10x Genomics? 10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com. This page (NASDAQ:TXG) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.